- Home
- SHLS vs MYGN Comparison
SHLS vs MYGN Comparison
Compare SHLS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- MYGN
- Stock Information
- Founded
- SHLS 1996
- MYGN 1991
- Country
- SHLS United States
- MYGN United States
- Employees
- SHLS N/A
- MYGN N/A
- Industry
- SHLS Semiconductors
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SHLS Technology
- MYGN Health Care
- Exchange
- SHLS Nasdaq
- MYGN Nasdaq
- Market Cap
- SHLS 660.1M
- MYGN 744.7M
- IPO Year
- SHLS 2021
- MYGN 1995
- Fundamental
- Price
- SHLS $3.30
- MYGN $7.29
- Analyst Decision
- SHLS Buy
- MYGN Hold
- Analyst Count
- SHLS 23
- MYGN 16
- Target Price
- SHLS $9.43
- MYGN $20.17
- AVG Volume (30 Days)
- SHLS 5.3M
- MYGN 1.2M
- Earning Date
- SHLS 05-06-2025
- MYGN 05-06-2025
- Dividend Yield
- SHLS N/A
- MYGN N/A
- EPS Growth
- SHLS N/A
- MYGN N/A
- EPS
- SHLS 0.14
- MYGN N/A
- Revenue
- SHLS $399,208,000.00
- MYGN $837,600,000.00
- Revenue This Year
- SHLS $9.23
- MYGN $2.99
- Revenue Next Year
- SHLS $11.89
- MYGN $8.36
- P/E Ratio
- SHLS $23.64
- MYGN N/A
- Revenue Growth
- SHLS N/A
- MYGN 11.21
- 52 Week Low
- SHLS $2.71
- MYGN $7.35
- 52 Week High
- SHLS $9.17
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- SHLS 47.84
- MYGN 25.95
- Support Level
- SHLS $2.92
- MYGN $7.69
- Resistance Level
- SHLS $3.44
- MYGN $8.27
- Average True Range (ATR)
- SHLS 0.33
- MYGN 0.56
- MACD
- SHLS 0.02
- MYGN 0.02
- Stochastic Oscillator
- SHLS 45.78
- MYGN 1.02
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.